User profiles for Brian Yu

Brian Yu

Stanford University
Verified email at stanford.edu
Cited by 233

[PDF][PDF] Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients

…, F Mo, M Lai, R Ho, K Cheung, BKH Yu… - Journal of clinical …, 2007 - academia.edu
… Michael KM Kam, Sing-Fai Leung, Benny Zee, Ricky MC Chau, Joyce JS Suen, Frankie Mo,
Maria Lai, Rosalie Ho, Kin-yin Cheung, Brian KH Yu, Samuel KW Chiu, Peter HK Choi, Peter …

Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma

…, SF Leung, AD King, F Mo, MK Kam, BK Yu… - Journal of clinical …, 2009 - ascopubs.org
Purpose To compare the toxicities, tumor control, survival, and quality of life of nasopharyngeal
cancer (NPC) patients treated with sequential neoadjuvant chemotherapy followed by …

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority …

…, CJ Bruno, JA Huntington, G Lin, B Yu… - The Lancet Infectious …, 2019 - thelancet.com
Background Nosocomial pneumonia due to antimicrobial-resistant pathogens is associated
with high mortality. We assessed the efficacy and safety of the combination antibacterial …

Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples

…, AB Heath, L Cook, AK Petrich, B Yu… - Clinical Infectious …, 2016 - academic.oup.com
Background. Interassay harmonization of cytomegalovirus (CMV) DNA measurement is
important for infection management. Uncertainty exists regarding the result harmonization …

[HTML][HTML] Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction

T Shimizu, N Narang, P Chen, B Yu, M Knapp… - JCI insight, 2017 - ncbi.nlm.nih.gov
Although left ventricular (LV) diastolic dysfunction is often associated with hypertension, little
is known regarding its underlying pathophysiological mechanism. Here, we show that the …

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill …

…, JL Kuti, KB Larson, E Gadzicki, B Yu… - Journal of …, 2020 - academic.oup.com
Objectives Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated
bacterial pneumonia at double the dose (ie 2 g/1 g) recommended for other indications. We …

ROCK as a therapeutic target for ischemic stroke

N Sladojevic, B Yu, JK Liao - Expert review of neurotherapeutics, 2017 - Taylor & Francis
Introduction: Stroke is a major cause of disability and the fifth leading cause of death.
Currently, the only approved acute medical treatment of ischemic stroke is tissue plasminogen …

Tocilizumab as a therapeutic agent for critically ill patients infected with sARS‐CoV‐2

…, DW Hines, BP Harting, K Sidwha, B Yu… - Clinical and …, 2021 - Wiley Online Library
Tocilizumab is an IL‐6 receptor antagonist with the ability to suppress the cytokine storm in
critically ill patients infected with severe acute respiratory syndrome‐coronavirus 2 (SARS‐…

Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening

B Yu, N Sladojevic, JE Blair, JK Liao - Expert opinion on therapeutic …, 2020 - Taylor & Francis
Introduction: Pathological cardiac fibrosis, through excessive extracellular matrix protein
deposition from fibroblasts and pro-fibrotic immune responses and vascular stiffening is …

Pharmacokinetics and safety of single intravenous doses of ceftolozane/tazobactam in children with proven or suspected Gram-negative infection

…, ML Rizk, L Caro, S Yang, B Yu… - The Pediatric …, 2018 - journals.lww.com
Background: Drug-resistant Gram-negative bacteria are a growing threat to children; thus
new antibiotics are needed to treat infections caused by these pathogens. Ceftolozane/…